All In Biotech

Drug Trial Radar · NCT06635785

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

387

Planned (sponsor's estimate)

Start

Mar 26, 2025

Primary completion

Jun 30, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
OncoC4, Inc.Industry
Sponsor type
Industry
First posted
Oct 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • AI-081Drug

    AI-081 is a humanized monoclonal antibody targeting PD-1 and VEGF.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD)Time frame: 21 Days
  2. Dose Limiting Toxicity (DLT)Time frame: 21 Days

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • University of Florida UF Health Cancer Center

    Gainesville, Florida · Recruiting

  • Memorial Healthcare System

    Hollywood, Florida · Recruiting

  • Ocala Oncology Center PL DBA Florida Cancer Affiliates

    Ocala, Florida · Recruiting

  • AdventHealth Cancer Institute

    Orlando, Florida · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Norton Cancer Center

    Louisville, Kentucky · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Health

    Detroit, Michigan · Recruiting

  • The Tisch Cancer Institute, Mount Sinai Medical Center

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill Cancer Center

    Chapel Hill, North Carolina · Recruiting

  • Duke University Medical Center - Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Novant Health Cancer Institute

    Winston-Salem, North Carolina · Recruiting

  • The Ohio State University James Cancer Center

    Columbus, Ohio · Recruiting

  • Prisma Health

    Greenville, South Carolina · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • University of Texas Health San Antonio Mays Cancer Center

    San Antonio, Texas · Recruiting

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.